Literature DB >> 1750416

Use of bisphosphonates in the prevention of bone loss and fractures.

A M Parfitt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1750416     DOI： 10.1016/0002-9343(91)90246-t

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  6 in total

1.  Bisphosphonates and vertebral fracture: an epidemiological perspective.

Authors:  C Cooper; I Fogelman; L J Melton
Journal:  Osteoporos Int       Date:  1991-10       Impact factor: 4.507

2.  Temporal relationship between bone loss and increased bone turnover: a longitudinal study following natural menopause.

Authors:  R Rosso; S Minisola; A Scarda; M T Pacitti; V Carnevale; E Romagnoli; G F Mazzuoli
Journal:  J Endocrinol Invest       Date:  1995-10       Impact factor: 4.256

Review 3.  Use of highly potent bisphosphonates in the treatment of osteoporosis.

Authors:  Michael McClung
Journal:  Curr Osteoporos Rep       Date:  2003-12       Impact factor: 5.096

Review 4.  Remodeling and the repair of fatigue damage.

Authors:  D B Burr
Journal:  Calcif Tissue Int       Date:  1993       Impact factor: 4.333

5.  Biomechanical effects of simulated resorption cavities in cancellous bone across a wide range of bone volume fractions.

Authors:  Sarah K Easley; Michael T Chang; Dmitriy Shindich; Christopher J Hernandez; Tony M Keaveny
Journal:  J Bone Miner Res       Date:  2012-09       Impact factor: 6.741

6.  The sclerostin-neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6.

Authors:  V Boschert; C Frisch; J W Back; K van Pee; S E Weidauer; E-M Muth; P Schmieder; M Beerbaum; A Knappik; P Timmerman; T D Mueller
Journal:  Open Biol       Date:  2016-08       Impact factor: 6.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.